Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken
Aandeel

Merus NV NL0011606264

Vertraagde koers (usd)

48,360

  • Verschill

    0,000 0,00%

  • Volume

    70 Gem. (3M) 608,3K

  • Bied

    19,350  

  • Laat

    77,370  
+ Toevoegen aan watchlist

Merus NV forum geopend

1.038 Posts
Pagina: «« 1 ... 15 16 17 18 19 ... 52 »» | Laatste | Omlaag ↓
  1. [verwijderd] 11 maart 2018 14:46

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Das al een flinke boterham. Wat is je gemiddelde aankoopprijs? Denk je aan tussentijds winst proberen te nemen of blijf je gewoon zitten?
  2. nelis h 11 maart 2018 17:08

    • nelis h

      Lid sinds: 01 jan 2000

      Laatste bezoek: 20 mrt 2024

    • Aanbevelingen

      Ontvangen: 711

      Gegeven: 734

    •    Aantal posts: 3.130

    beurswaarde moet eerst naar minimaal een miljard voor ik uit stap.
    een ArgenX-je kan ik wel een jaartje op wachten
  4. [verwijderd] 13 maart 2018 13:02

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Goed nieuws uiteindelijk bepaald de IP mede de waarde

    UTRECHT, The Netherlands, March 13, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that it has expanded its intellectual property portfolio with two newly issued U.S. Patents. The first covers clinical drug candidate MCLA-117, a Biclonics® that binds to CD3 and CLEC12A, and the second concerns Merus’ Spleen to Screen® technology that permits efficient screening of common light chain antibodies for generating Biclonics® lead candidates.

    On March 13, 2018, the United States Patent and Trademark Office (USPTO) granted U.S. Patent No. 9,914,777 (’777 patent), entitled “Human CD3 Binding Antibody”, covering MCLA-117, a Biclonics® that is designed to bind to CD3, a cell-surface molecule present on all T-cells, and to CLEC12A, a first-in-class target, expressed on the tumor cells and tumor stem cells of patients with acute myeloid leukemia (AML). Due to its prevalence in AML and restricted expression on some normal hematopoietic cells, we believe CLEC12A represents an attractive molecule for targeted therapy. The claims of the ‘777 patent concern Merus’ Biclonics®, and MCLA-117 in particular, that engage T-cells with tumor cells by targeting CD3 and a tumor-antigen, including CLEC12A. MCLA-117 is currently being studied in an ongoing Phase 1, first-in-human, dose escalation clinical trial in Europe in AML patients with relapsed or refractory disease, and obtained acceptance in February 2018 by the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application filed earlier this year.

    On March 6, 2018, the USPTO also granted U.S. Patent No. 9,908,946 (’946 patent) entitled, “Generation of Binding Molecules,” which concerns Merus’ proprietary Spleen to Screen® technology, a part of its Biclonics® technology platform. The ‘946 patent claims techniques to efficiently screen panels of common light chain antibodies, designed to allow Merus to rapidly identify and generate therapeutic candidates with differentiated modes of action.

    “The issuance of Merus’ first U.S. Patent covering MCLA-117, marks yet another milestone in the advancement of this promising clinical candidate, which, along with the patent issuance covering our Spleen to Screen® technology, adds further intellectual property protection related to our clinical candidates and bispecific antibody platform based on our proprietary Biclonics® technology,” said Dr. Ton Logtenberg, Chief Executive Officer of Merus.

    As of March 13, 2018, Merus’ patent portfolio related to its bispecific antibody candidate MCLA-117 consists of additional pending applications in the U.S., Europe and an array of foreign countries. Merus has also obtained patents around the globe, including throughout Europe, Asia, Australia and the U.S. related to its Spleen to Screen® technology, with other applications still pending in the U.S. and abroad.

    These two recent issuances by the USPTO reported here bolster Merus’ substantial patent estate related to the panoply of Biclonics® technologies, including transgenic rodents, production of antibody libraries, screening methods, Fc engineering, antibody host cell expression and preclinical and clinical bispecific antibody candidates.
  6. Pokerface 14 maart 2018 12:08

    • Pokerface

      Lid sinds: 27 mrt 2001

      Laatste bezoek: 06 mei 2024

    • Aanbevelingen

      Ontvangen: 979

      Gegeven: 1202

    •    Aantal posts: 3.891

    MERUS ANNOUNCES ONO PHARMACEUTICALS EXERCISE OF ITS OPTION FOR NEW RESEARCH AND LICENSE AGREEMENT TO GENERATE BISPECIFIC ANTIBODY TARGETING AUTOIMMUNE DISEASES

    UTRECHT, The Netherlands, March 14, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ono Pharmaceutical Co., LTD. (Osaka, Japan, ‘Ono’) has exercised its option under an agreement executed in April 2014 to enter into a new research and license agreement utilizing Merus’ proprietary Biclonics® technology platform to generate a bispecific antibody that binds to a combination of targets designed for the treatment of autoimmune diseases.

    “Ono’s decision to exercise its option builds on the success to date of the original collaboration we entered into in 2014,” said Ton Logtenberg, Ph.D., Chief Executive Officer of Merus. “As we continue to advance and expand Merus’ proprietary pipeline of innovative therapeutic candidates in oncology, we are very excited to work with a collaborator such as Ono to leverage our Biclonics® technology platform to develop therapeutics for other disease areas with significant unmet medical needs.”

    "We highly value Merus’ proprietary drug discovery technology which effectively generates full-length human bispecific antibody therapeutics," said Hiromu Habashita, Ph.D., Corporate Officer, and Executive Director of Discovery & Research of Ono. "We are glad to expand our collaboration and look forward to realizing the next generation of high value treatments in autoimmune disease area.”

    In April 2014, Merus and Ono entered into a research and license agreement to jointly develop bispecific antibody therapies for autoimmune diseases. In 2016, Ono selected a lead bispecific antibody candidate that it intends to advance into clinical testing, which triggered a milestone payment to Merus. By exercising its option under the terms of the first agreement, Ono has agreed to fund research activities at Merus that will generate candidate Biclonics® for the new program. Merus has granted Ono worldwide exclusive rights to develop, manufacture, and commercialize the resulting products developed through the collaboration.

    Consistent with the terms of Merus’ 2014 agreement, under the new agreement, Merus will receive an undisclosed upfront payment. Merus is also eligible to receive milestone payments upon achievement of specified research and clinical development milestones. For products commercialized under this agreement, if any, Merus is also eligible to receive a mid-single digit royalty on net sales.

    Bron: phoenix.corporate-ir.net/phoenix.zhtm...
  17. forum rang 6 Tom3 15 maart 2018 22:55

    • Tom3

      Lid sinds: 25 jan 2015

      Laatste bezoek: 06 mei 2024

    • Aanbevelingen

      Ontvangen: 2790

      Gegeven: 596

    •    Aantal posts: 11.006

    quote:

    fly like an eagle schreef op 14 maart 2018 12:33:

    Zeer goed nieuws!
    De beurs heeft het echter allemaal voor kennisgeving aangenomen:-5,6% vandaag. Ook hier gaat men pas in actie komen als men bij wijze van spreken de dollarbiljetten ruiken kan. Wanneer komen nu die fase 1 resultaten mbt #117? Ze wilden zeker eerst het patent veilig stellen, waarom trouwens?
1.038 Posts
Pagina: «« 1 ... 15 16 17 18 19 ... 52 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in
Premium

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van BeursDuivel en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 55% korting!

Word abonnee

Laatste Nieuws

  1. Europese beurzen hoger rond middaguur
  2. Bijna alle hoofdaandelen hoger in Brussel
  3. Producentenprijzen eurozone blijven dalen
  4. Beursblik: Kepler verhoogt koersdoel GBL
  5. Groei in dienstensector eurozone trekt verder aan
  6. Must read: "I hope I come next year"
  7. Duitse dienstensector groeit verder
  8. Franse dienstensector groeit weer
  9. Groeitempo Italiaanse dienstensector licht omlaag
  10. Spaanse dienstensector groeit nog iets harder
  11. Reduceren-advies van Kepler Cheuvreux voor Colruyt
  12. Bel20 opent iets hoger, Argenx aan kop

Meest Gelezen Premium

  1. Premium Premium
    Advieswijziging ASML
  2. Premium Premium
    Iets langer geduld met Besi
  3. Premium Premium
    Tijd om het aandeel Adyen op te vissen?
  4. Premium Premium
    Uitstekende cijfers Flow Traders
  5. Premium Premium
    Modelportefeuilles: dit aandeel koerst 40% hoger, maar er zit nog meer in het vat
  6. Premium Premium
    Resultaten Microsoft zijn wake-up call: AI zorgt voor extra groei
  7. Premium Premium
    Een chipaandeel met opvallend hoog dividendrendement

Beleggingsideeën van onze partners

Macro & Bedrijfsagenda

  1. 06 mei

    1. China inkoopmanagersindex diensten april
    2. PostNL Q1-cijfers
    3. Siemens Healthineers Q1-cijfers
    4. TKH Q1-cijfers
    5. Dui inkoopmanagersindex diensten april (def)
    6. EU inkoopmanagersindex diensten april (def) 52,9
    7. VK inkoopmanagersindex diensten april (def)
    8. EU producentenprijzen maart
    9. Tyson Foods Q1-cijfers

  2. 07 mei

    1. Japan inkoopmanagersindex diensten april
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda